Phaseline

Companies › InSightec

InSightec: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jun 2031.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Blood Brain Barrier Opening - Oncology (Exablate BBBO)
Blood-brain barrier opening via focused ultrasound with microbubbles
–Phase 3Brain TumorJun 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05317858Blood Brain Barrier Opening - Oncology (Exablate BBBO)Phase 3Brain TumorOncologyJun 2031

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

SynOx Therapeutics NingBo Junyan Hongshi Biosciences Taizhou Hanzhong biomedical NovoCure Summit Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.